Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 60, Issue 3, pp 309–312 | Cite as

The contribution of Gianni Bonadonna to the history of chemotherapy

  • Domenico Ribatti
Review

Abstract

The history of cancer chemotherapy and of the discipline of medical oncology has been that of drug discovery. The pioneering discoveries of the early days of chemotherapy have allowed the development of a paradigm for drug discovery that persists, with modifications to the present day. This review article summarizes the seminal work of the Italian scientist Gianni Bonadonna on the treatment of breast cancer and Hodgkin’s disease.

Keywords

Breast cancer Chemotherapy History of medicine Hodgkin’s disease Tumor 

Notes

Acknowledgments

This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, Regional Funds), Milan, the Ministry for the Universities and Research (FIRB 2001 and PRIN 2005), Rome and Fondazione Italiana per la Lotta al Neuroblastoma, Genoa, Italy.

References

  1. 1.
    Marchall EK Jr (1964) Historical perspectives in chemotherapy. Adv Chemother 1:1Google Scholar
  2. 2.
    Fisher B, Gebhardt MC (1978) The evolution of breast cancer surgery: past, present and future. Semin Oncol 5:385–394PubMedGoogle Scholar
  3. 3.
    Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC (1974) Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218–220PubMedGoogle Scholar
  4. 4.
    Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC (1976) Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 84:389–392PubMedGoogle Scholar
  5. 5.
    De Lena M, Brambilla C, Morabito A, Bonadonna G (1975) Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35:1108–1115PubMedCrossRefGoogle Scholar
  6. 6.
    Brambilla C, De Lena M, Rossi A, Valgussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1:801–804PubMedGoogle Scholar
  7. 7.
    Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, Band PR (1976) Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with l-phenylalanine mustard. Cancer 38:1882–1886PubMedCrossRefGoogle Scholar
  8. 8.
    Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combined chemotherapy as adjuvant treatment in operable breast cancer. New Engl J Med 294:405–410PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher B, Carbone P, Economou SG et al (1975) l-Phenylalanine mustard (l-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292:117–122PubMedCrossRefGoogle Scholar
  10. 10.
    Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, metotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New Engl J Med 332:901–906PubMedCrossRefGoogle Scholar
  11. 11.
    Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 Years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217PubMedCrossRefGoogle Scholar
  12. 12.
    Hersh SM (1968) Chemical and biological warfare: America’s hidden arsenal. Bobbs Merrill, New YorkGoogle Scholar
  13. 13.
    Infield GB (1971) Disaster at Bari. MacMillan, New YorkGoogle Scholar
  14. 14.
    Gilman A, Philips FS (1946) The biological actions and therapeutic applications of b-chloroethyl amines and sulfides. Science 103:409–415CrossRefPubMedGoogle Scholar
  15. 15.
    Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman AZ, McLennan MJ (1946) Nitrogen mustard therapy. Use of methyl-bis (beta-chloroethyl) amino hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 132:126–132Google Scholar
  16. 16.
    Scott IL (1963) The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin’s disease. Cancer Chemother Rep 27:27–32PubMedGoogle Scholar
  17. 17.
    Skipper H, Schabel F, Wilcox W (1964) Experimental evaluation of potential anticancer agents. Cancer Chemother Rep 35:1–111PubMedGoogle Scholar
  18. 18.
    Moxley J, De Vita VJ, Brace K, Frei E (1976) Intensive chemotherapy and X-irradiation in Hodgkin’s disease. Cancer 27:1258–1263Google Scholar
  19. 19.
    Lacher MJ, Durant J (1965) Combined vinblastine and chlorambucil therapy of Hodgkin’s disease. Ann Intern Med 62:468–476PubMedGoogle Scholar
  20. 20.
    De Vita VT, Serpick A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895Google Scholar
  21. 21.
    De Vita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC (1975) Combination chemotherapy in the treatment of Hodgkin’s disease. Ann Intern Med 73:881–895Google Scholar
  22. 22.
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259PubMedCrossRefGoogle Scholar
  23. 23.
    Bonadonna G, Beretta G, Tancini G et al (1975) Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep 6:231–245Google Scholar
  24. 24.
    Bonadonna G (1982) Chemotherapy strategies to improve the control of Hodgkin’s disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42:4309–4320PubMedGoogle Scholar
  25. 25.
    Bonadonna G, Santoro A (1982) ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9:21–35PubMedCrossRefGoogle Scholar
  26. 26.
    Bonadonna G, Santoro A (1982) Evolution in the treatment strategy of Hodgkin’s disease. Adv Cancer Res 36:257–293PubMedCrossRefGoogle Scholar
  27. 27.
    Santoro A, Bonadonna G, Valagussa P et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease. Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27–38PubMedGoogle Scholar
  28. 28.
    Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 104:739–746PubMedGoogle Scholar
  29. 29.
    Viviani S, Bonadonna G, Santoro A et al (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease, ten years results. J Clin Oncol 14:1421–1430PubMedGoogle Scholar
  30. 30.
    Canellos GP, Anderson JR, Propert KJ et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, ABVD or MOPP alternating with ABVD. New Engl J Med 327:1478–1484PubMedCrossRefGoogle Scholar
  31. 31.
    Duggan DB, Petroni GR, Johnson L et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease, report of an intergroup trial. J Clin Oncol 21:607–614PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Human Anatomy and HistologyUniversity of Bari Medical SchoolBariItaly

Personalised recommendations